BillionToOne

PORTFOLIO - BillionToOne

BillionToOne
life-sciences

Molecular diagnostics company

Detect disease, one molecule at a time

BillionToOne, headquartered in Menlo Park, California, is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The Company’s QCT molecular counter platform is the only technology that can count DNA molecules at the single-count level with single base-pair precision. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D.

On March 30, 2022 BillionToOne closed Series C funding round of $125 million with premier global investors. This round was co-led by incoming investor Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others. Fark Labs invested in BillionToOne in this Series C funding round. This Series C funding will be used to expand BillionToOne’s commercial and clinical teams, scale up lab capacity, and conduct clinical studies for their liquid biopsy test. “Our prenatal test is solving a critical unmet medical need. We continue to grow at an incredible rate, and we are building out an ever-increasing set of larger laboratory facilities. The current funding will be used to support our prenatal test growth while launching our differentiated liquid biopsy test that will transform oncology care,” said Oguzhan Atay, Ph.D., co-founder and CEO of BillionToOne. Click here to read the press release.